New developments in investigational HDAC inhibitors for the potential multimodal treatment of cachexia
出版年份 2018 全文链接
标题
New developments in investigational HDAC inhibitors for the potential multimodal treatment of cachexia
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 28, Issue 2, Pages 179-189
出版商
Informa UK Limited
发表日期
2018-12-10
DOI
10.1080/13543784.2019.1557634
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Aspirin-inspired acetyl-donating HDACs inhibitors
- (2018) Jiah Lim et al. ARCHIVES OF PHARMACAL RESEARCH
- HDAC11 is a regulator of diverse immune functions
- (2018) Cansu Yanginlar et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells
- (2018) Julius C. Enßle et al. CANCER LETTERS
- Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors
- (2018) Sandra Atlante et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- New mechanisms driving muscle stem cell regenerative decline with aging
- (2018) Pedro Sousa-Victor et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Histone deacetylase inhibitor (HDACi) upregulates activin A and activates the Smad signaling pathway in melanomas
- (2018) Jeeyong Lee et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Effects of Class II-Selective Histone Deacetylase Inhibitor on Neuromuscular Function and Disease Progression in SOD1-ALS Mice
- (2018) Daniela Buonvicino et al. NEUROSCIENCE
- Modulating Metabolism to Improve Cancer-Induced Muscle Wasting
- (2018) Fabio Penna et al. Oxidative Medicine and Cellular Longevity
- A translational perspective on histone acetylation modulators in psychiatric disorders
- (2018) Surajit Ganguly et al. PSYCHOPHARMACOLOGY
- Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
- (2018) Amit Singh et al. Nutrients
- Blocking extracellular activation of myostatin as a strategy for treating muscle wasting
- (2018) M. Pirruccello-Straub et al. Scientific Reports
- Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
- (2018) Alexander S. Hölscher et al. Clinical Epigenetics
- Histone Deacetylase Inhibitors and Diabetic Kidney Disease
- (2018) Mitchell Hadden et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
- (2018) Malgorzata Ziemka-Nalecz et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure
- (2018) Levi Evans et al. Nutrients
- The HDAC6 Inhibitor Tubacin Induces Release of CD133+ Extracellular Vesicles From Cancer Cells
- (2017) Olivia S. Chao et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- The Role of Exercise and TFAM in Preventing Skeletal Muscle Atrophy
- (2017) Nicholas T. Theilen et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Update on Management of Cancer-Related Cachexia
- (2017) Lindsey J. Anderson et al. Current Oncology Reports
- Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival
- (2017) Marco Segatto et al. Nature Communications
- What is next after anamorelin?
- (2017) Jose M. Garcia Current Opinion in Supportive and Palliative Care
- Interference with Ca2+-Dependent Proteolysis Does Not Alter the Course of Muscle Wasting in Experimental Cancer Cachexia
- (2017) Fabrizio Pin et al. Frontiers in Physiology
- Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia
- (2016) Rulin Sun et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation
- (2016) Lianmin Bao et al. CELL BIOLOGY AND TOXICOLOGY
- Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities
- (2016) Erin E. Talbert et al. MOLECULAR CANCER THERAPEUTICS
- Concise Review: Epigenetic Regulation of Myogenesis in Health and Disease
- (2016) Marie-Claude Sincennes et al. Stem Cells Translational Medicine
- Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42
- (2016) Sally E. Henderson et al. NEOPLASIA
- The histone deacetylase inhibitor butyrate improves metabolism and reduces muscle atrophy during aging
- (2015) Michael E. Walsh et al. AGING CELL
- Sirtuins: double players in Huntington's disease
- (2015) Luana Naia et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Cachexia: A preventable comorbidity of cancer. A T.A.R.G.E.T. approach
- (2015) Maurizio Muscaritoli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Epigenetic changes as a common trigger of muscle weakness in congenital myopathies
- (2015) Ori Rokach et al. HUMAN MOLECULAR GENETICS
- Trichostatin A, a histone deacetylase inhibitor, modulates unloaded-induced skeletal muscle atrophy
- (2015) Sylvie Dupré-Aucouturier et al. JOURNAL OF APPLIED PHYSIOLOGY
- Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia
- (2015) Yu-Chou Tseng et al. JNCI-Journal of the National Cancer Institute
- Differential expression ofHDACandHATgenes in atrophying skeletal muscle
- (2015) Adam W. Beharry et al. MUSCLE & NERVE
- Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting
- (2015) Fabio Penna et al. Journal of Cachexia Sarcopenia and Muscle
- Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved
- (2015) Ji-an Chen et al. Journal of Cachexia Sarcopenia and Muscle
- Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia
- (2015) Yu-Chou Tseng et al. JNCI-Journal of the National Cancer Institute
- Cancer cachexia, mechanism and treatment
- (2015) Tomoyoshi Aoyagi et al. World Journal of Gastrointestinal Oncology
- Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: From sarcopenic obesity to cachexia
- (2014) Gianni Biolo et al. CLINICAL NUTRITION
- Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)
- (2014) J. Lee et al. CURRENT MEDICINAL CHEMISTRY
- Coming back
- (2014) Fabio Penna et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- Histone Deacetylase 6 Is a FoxO Transcription Factor-dependent Effector in Skeletal Muscle Atrophy
- (2014) Francesca Ratti et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7
- (2014) W. A. He et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?
- (2013) Carla M Prado et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Reply to “Letter to the editor: ‘The origin of free glutamate in milk: a role for anionic amino acid transporters’”
- (2013) Takuya Matsumoto et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Rôle de l’Activine A et de la Myostatine dans la cachexie cancéreuse
- (2013) Jean-Paul Thissen et al. ANNALES D ENDOCRINOLOGIE
- SIRT1 Protein, by Blocking the Activities of Transcription Factors FoxO1 and FoxO3, Inhibits Muscle Atrophy and Promotes Muscle Growth
- (2013) Donghoon Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- NF-κB–mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia
- (2013) Wei A. He et al. JOURNAL OF CLINICAL INVESTIGATION
- Unknown
- (2013) Silvia Consalvi et al. MOLECULAR MEDICINE
- BMP signaling controls muscle mass
- (2013) Roberta Sartori et al. NATURE GENETICS
- Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
- (2012) C M M Prado et al. BRITISH JOURNAL OF CANCER
- SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial Function
- (2012) Nathan L. Price et al. Cell Metabolism
- Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes
- (2012) M. A. Niewczas et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Posttranslational modifications control FoxO3 activity during denervation
- (2011) Enrico Bertaggia et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Increased serum levels of S100B are related to the severity of cardiac dysfunction, renal insufficiency and major cardiac events in patients with chronic heart failure
- (2011) Jin Ping Li et al. CLINICAL BIOCHEMISTRY
- The Physical and Biological Characterization of a Frail Mouse Model
- (2011) J. Walston et al. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
- Definition and classification of cancer cachexia: an international consensus
- (2011) Kenneth Fearon et al. LANCET ONCOLOGY
- STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia
- (2011) Andrea Bonetto et al. PLoS One
- Mammalian Sirtuins: Biological Insights and Disease Relevance
- (2010) Marcia C. Haigis et al. Annual Review of Pathology-Mechanisms of Disease
- Myogenin and Class II HDACs Control Neurogenic Muscle Atrophy by Inducing E3 Ubiquitin Ligases
- (2010) Viviana Moresi et al. CELL
- Transcription activation of myostatin by trichostatin A in differentiated C2C12 myocytes via ASK1-MKK3/4/6-JNK and p38 mitogen-activated protein kinase pathways
- (2010) Der-Sheng Han et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Muscle Wasting and Impaired Myogenesis in Tumor Bearing Mice Are Prevented by ERK Inhibition
- (2010) Fabio Penna et al. PLoS One
- Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia
- (2009) Margaret E. Benny Klimek et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Deacetylase Inhibitors Modulate the Myostatin/Follistatin Axis without Improving Cachexia in Tumor-Bearing Mice
- (2009) A. Bonetto et al. CURRENT CANCER DRUG TARGETS
- PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
- (2009) Carles Cantó et al. CURRENT OPINION IN LIPIDOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started